A Double-blind, Randomized, Placebo-controlled, Parallel, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-00547659 In Subjects With Moderate To Severe Ulcerative Colitis (Turandot)
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs SHP 647 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms TURANDOT
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 18 May 2017 According to a shire media release, results were published in the May 17, 2017 issue of The Lancet.
- 17 May 2017 Results published in the THE LANCET.